. Author manuscript; available in PMC: 2021 Feb 15.

Published in final edited form as: Eur J Haematol. 2018 Oct 23;102(1):20–35. doi: 10.1111/ejh.13172

TABLE 1.

2017 European LeukemiaNet risk stratification by genetics¹³

Risk category	Genetic abnormality
Favorable	t(8;21)(q22;q22.1); RUNX1-RUNX1T1 inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11 Mutated NPM1 without FLT3-ITD or with FLT3-ITD low^b Biallelic mutated CEBPA
Intermediate	Mutated NPM1 and FLT3-ITD high^b Wild-type NPM1 without FLT3-ITD or with FLT3-ITD low^b (w/o adverse-risk genetic lesions) t(9;11)(p21.3;q23.3); MLLT3-KMT2A^c Cytogenetic abnormalities not classified as favorable or adverse
Adverse	t(6;9)(p23;q34.1); DEK-NUP214 t(v;11q23.3); KMT2A rearranged t(9;22)(q34.1;q11.2); BCR-ABL1 inv(3)(q21.3q26.2) or t(3;3)(q21.3;q26.2); GATA2, MECOM(EVI1) −5 or del(5q); −7; −17/abn(17p) Complex karyotype,^d monosomal karyotype^a Wild-type NPM1 and FLT3-ITD high^b Mutated RUNX1^e Mutated ASXL1^e Mutated TP53^f

Modified according to Ref.¹³ Defined by the presence of one single monosomy (excluding loss of X or Y) in association with at least one additional monosomy or structural chromosome abnormality (excluding core-binding factor AML).¹³

Low, low allelic ratio (<0.5); high, high allelic ratio (>0.5); as determined by GeneScan analysis.

The presence of t(9;11)(p21.3;q23.3) takes precedence over rare, concurrent adverse-risk gene mutations.

Three or more unrelated chromosome abnormalities in the absence of one of the World Health Organization-designated recurring translocations or inversions, that is, t(8;21), inv(16) or t(16;16), t(9;11), t(v;11)(v;q23.3), t(6;9), inv(3) or t(3;3); AML with BCR-ABL1.

These markers should not be used as an adverse prognostic marker if they co-occur with favorable-risk AML subtypes.

TP53 mutations are significantly associated with AML with complex and monosomal karyotype.¹³²